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ABSTRACT  
Background 
 
It is not known when in the course of incurable cancer referral to a specialist palliative 
care service should optimally be made.   
 
Methods 
 
We randomly assigned patients with newly detected incurable metastatic cancer with an 
estimated survival of less than 12 months to receive either (1) standard oncologic care 
plus contact from a palliative care nurse who served as a link to palliative care services 
in the hospital and community (PC) or (2) standard oncologic care alone.  Quality of life 
(QoL) measures were assessed at baseline and monthly thereafter.  The primary 
endpoint was quality of life over time measured by the McGill QOL total score. 
 
Findings 
 
120 patients were randomized, 60 to each group.  Forty four patients had 
gastrointestinal cancer, 23 lung cancer, 19 gynaecological cancer and 17 breast cancer. 
The mean time since initial cancer diagnosis was 34 months in the standard care group 
and 29 months in the early palliative care contact group.   There was no evidence that 
early PC nurse contact reduced symptoms or improved quality of life. If anything, there 
was a trend towards the opposite. There were non-significant trends for the place of 
death of early contact PC patients to be other than in an acute hospital, and for greater 
PC input during their final acute hospital admission.  Early contact with palliative care 
was not found to influence the number of lines of chemotherapy received. 
 
Interpretation 
 
The study did not demonstrate a QoL benefit for early contact with a PC nurse. 
 
 
Funding 
 
Supported by an NHMRC strategic palliative care research grant no: 219141. 
Trial Registration: ACTRN12611001137987
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INTRODUCTION 
 
In cancer patients receiving chemotherapy, 35% experience distress (1) 70% 
experience nausea (2) while up to 33% experience severe diarrhoea (3).  A recent 
systematic review concluded that over half of people at the end stage of cancer have 
distress, pain, dyspnoea, and fatigue (4). A large proportion (30-40%) of cancer patients 
and carers reports significant unmet need for information, symptom relief and support 
(5, 6). 
 
Health professionals often delay discussion of end of life (EOL) issues until only days 
before death (7). For example, the US SUPPORT study documenting care for over 
9000 seriously ill hospitalised adults (8) reported that only 47% of physicians knew 
whether their patients preferred to avoid cardiopulmonary resuscitation (CPR), and 46% 
of do-not-resuscitate (DNR) orders were written within 2 days of death. Wright (9) found 
that EOL discussions conducted a median of 4.4 months before death were associated 
with less aggressive medical care near death and earlier hospice referrals. More 
aggressive medical care has been found to be associated with worse quality of life and 
no survival benefit.  
 
Early contact with palliative care services has the potential to overcome some of these 
distressing outcomes. The proportion of terminal cancer patients currently referred to 
palliative care services varies in Australia, and internationally.  Moreover there is wide 
variation in the time course of advanced cancer when patients are referred to palliative 
care for the first time. A study from Boston randomised 151 patients with newly 
diagnosed metastatic non-small cell lung cancer to receive either palliative care 
integrated with standard oncologic care or standard oncologic care alone (10). Patients 
assigned to early palliative care had a better quality of life at 12 weeks and fewer 
depressive symptoms than did patients assigned to standard care  
 
We report the results of a randomised trial of early contact with palliative care services 
in patients with newly detected incurable metastatic cancer.  We hypothesised that early 
contact with palliative care services would improve patients’ EOL experiences through 
better symptom control and quality of life; addressing patients’ supportive care needs; 
reducing the lines of chemotherapy delivered; and reducing the likelihood of dying in the 
acute hospital setting. It was anticipated that meeting and talking with a palliative care 
nurse at the time of recruitment would subsequently provide a pathway for patients to 
contact the palliative care service independent of the oncologist. It was hoped this 
facilitated access to the PC service would have the benefit of improved symptom 
control. 
 
1 METHODS 
1.1 Study Design and Intervention 
Between April 2003 to January 2005 ambulatory patients with newly detected incurable 
metastatic cancer attending a medical oncology clinic with a life expectancy of less 
than12 months were invited to take part in a randomised controlled trial of early contact 
with a palliative care nurse consultant with ongoing oncologist care or oncologist care 
alone.  For allocation of the participants, a computer-generated list of random numbers 
was used, and allocation was concealed using sequentially numbered, opaque sealed 
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envelopes.No stratification was made for oncologist or cancer diagnosis. A sample size 
of 150 patients was sought to provide over 80% power to detect an effect size of 0.50 
(standard deviations) at the two-sided 5% level of significance based on a two-sample t-
test; with even greater precision achievable using analyses incorporating the baseline 
score as a covariate (11).  
 
Patients assigned to the early palliative care group met with a palliative care nurse 
consultant (PC nurse) member of the hospital palliative care team. She outlined 
available palliative care services including advice about symptom control, and she 
offered to arrange review by a palliative care physician, and provided contact details for 
the palliative care service.  The PC nurse offered to telephone the patient monthly to 
check on their well-being, or, if the patient preferred, provided her contact details.  
Standard oncologic care was given in line with the oncologist’s recommendation.  
Control patients were referred to the palliative care service when recommended by the 
oncologist. 
 
1.2 Assessments and Endpoints 
 
At baseline, oncologists documented their estimate of the patient’s life expectancy (12).  
 
Symptom severity, feeling supported and overall QoL were pre-specified as being the 
key outcome measures. The severity of symptoms and overall quality of life were 
measured using the McGill quality of life (MQOL) questionnaire (13) and the Rotterdam 
Symptom Checklist (RSC) (14).  Construct validity of the MQOL has been demonstrated 
through its correlations with the Spitzer Quality of Life scale (15). Cronbach's alpha for 
subscales was moderate to high (0.462-0.858) and test-retest reliability 
(Spearman's r(s) ranged from 0.512-0.861 (16). Validity has been demonstrated 
through correlations with a range of related scales (17).   
 
The degree of perceived support was measured using the Supportive Care Needs – 
Short Form questionnaire (SCNS-short) (18).   Content and face validity has been found 
to be high and construct validity is supported by a robust factor structure (19). Patients 
were requested to complete the MQOL and RSC at monthly intervals and the SCNS-
short every 4 months.  
 
Other secondary endpoints collected from hospital medical records included end of life 
experiences, number of lines of chemotherapy, and place of death.  
 
1.3 Analysis Methods 
 
All analyses were performed in accordance with the intention-to-treat principle. 
Repeated measures analyses were undertaken on the longitudinal RSC, MQOL, and 
SCNS assessments using a mixed modeling approach with the baseline measure as a 
covariate and treatment group, assessment time point, and a treatment group-by-time 
point interaction as factors. The interaction term allowed the model to evaluate the 
difference between groups at each time point. Imputation of missing data was not 
required as mixed modeling methods accommodate unbalanced designs. A comparison 
was also performed between the groups on patients’ average scores over the follow-up 
period, and patients’ worst scores over the follow-up period, for the RSC, MQOL, and 
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SCNS assessments using an analysis of covariance with the baseline score fitted as the 
covariate. Treatment groups were compared on categorical variables measured at a 
single time point using a chi-squared test, or Fisher’s exact test where appropriate. 
Survival time in the two groups was compared using a log-rank test and presented 
graphically using Kaplan-Meier plots. Cox proportional hazards regression models were 
used to estimate hazard ratios for the treatment effect with and without adjustment for 
other predictors of survival.  
2 RESULTS 
2.1 Baseline Characteristics  
 
One hundred and twenty of the 141 patients approached consented to take part and 
were randomized to either the early referral group (N=60) or standard care (N=60). 
Recruitment to the study was halted at this point due to resource constraints. Forty four 
patients had a gastrointestinal primary cancer, 23 lung cancer, 19 gynaecological 
cancers, 17 breast cancer 2 prostate cancer and 15 other primary sites, or unknown. 
Most baseline characteristics were adequately balanced across the two study groups 
(Table 1), however there were differences between the groups in the time since initial 
cancer diagnosis (mean of 29 versus 34 months in the early referral and standard care 
groups respectively), and the oncologists’ estimate of likely survival (e.g. 11 versus 20 
patients with estimates of >12 months likely survival in the early referral and standard 
care groups respectively). Therefore these variables were controlled for in subsequent 
analyses. There were no remarkable baseline differences between the groups on the 
patient reported outcome measures.  
 
2.2 Contact with Palliative Care Services 
 
Initial contact:  Patients in the early palliative care contact group had at least one 
meeting with the PC nurse, with the median time to first contact being 2 weeks after 
randomisation. Further contact with the PC nurse was more frequent when the initial 
contact with the PC nurse was face to face.  Most patients were happy for the PC nurse 
to explore the role of palliative care, and for records of their response to be kept. 
Several patients stated they thought they were not ready for palliative care but were 
happy to have it explained.  Many patients reported feeling better having discussed 
palliative and end of life care options even though they were receiving anticancer 
treatments.  
 
Subsequent contact:  Many patients preferred to contact the PC nurse when they 
needed assistance rather than receiving monthly telephone contact, and many made 
contact during clinic attendance.  Twenty eight patients had 1 subsequent telephone 
contact with the PC nurse, 3 had 2-3 telephone contacts and 5 had more than 3.  Two 
patients preferred to telephone the PC nurse and did so.  20 patients had no 
subsequent contact with the palliative care nurse. The average number of telephone 
contacts with the PC nurse in the early contact group was 3. 
Fifty one patients in the early palliative care contact group were seen at least once by a 
palliative care physician consultant compared to 8 patients in the control group.  In the 
intervention group 25 patients were seen by a palliative care physician in the last few 
weeks of life (16 in the last month of life compared to 6 in the control group) 
6 
 
2.3 Quality of Life and Unmet Needs 
 
Data on patient-reported outcome measures were available on 107 of the 120 patients 
randomized at baseline (Figure 1). This number declined to 51 of 79 alive at 6 months, 
29 of 52 alive at 12 months, and 7 of 36 alive at 18 months. The median duration of 
follow-up on the self-reported outcome measures was 4.8 versus 8.1 months for the 
early referral and standard care groups respectively (p-value = 0.13).  
 
There was no evidence that early PC intervention was superior to the control on patient 
reported measures.  Figures 2 and 3 summarize the estimates for the two groups over 
the first 12 months of follow-up on the MQOL total score, the RSCL physical symptom 
scale and the RSCL psychological distress scale.  Across these measures there were 
consistent post baseline trends of modest magnitude favouring the control arm with 
differences that occasionally reached statistical significance. These results were not 
materially changed when adjusted for the oncologist’s baseline estimate of likely 
survival, diagnosis, months since diagnosis, and gender were included as covariates 
(results presented in e-supplement). 
 
Table 2 presents a summary of the symptoms ever reported on the MQoL as severe 
(i.e. assigned a score > 5) by the 47 patients who completed an assessment within the 
three months prior to death.  Unexpectedly, somewhat more patients in the early PC 
intervention group than in the control group had severe scores for pain and poor 
appetite. 
 
2.4 Cancer treatment and PC input during the final acute hospital 
 
Patients from both groups received an average of 1.8 lines of chemotherapy. Forty-two 
patients (42/49 86%) randomized to the early referral group received palliative care 
contact during the last acute hospital admission compared to 29 patients (29/37 78%) in 
the control group (p=0.37).  
2.5 Survival 
 
The median survival of the early PC contact group was 7.0 months (95% CI: 5.2-9.8) 
compared to 11.7 months (95% CI: 9.8-18.8) for the standard care group (log rank 
p=0.014) (Fig 3). The estimated hazard ratio was 1.6 (95%CI: 1.1 to 2.3; p=0.015). This 
estimate changed to 1.5 (95%CI 0.99 to 2.2; p=0.06) when adjusted for the oncologist’s 
baseline estimate of likely survival, diagnosis, months since diagnosis, and gender.  
 
3.6 Place of death 
 
There was little evidence of a difference between randomization groups in terms of 
place of death (Table 3). Only 2 patients (both early palliative care contact group) were 
admitted to ICU during their final acute hospital admission. One patient had attempted 
cardiopulmonary resuscitation (early palliative care contact group), and 2 had 
mechanical ventilation (1 in each group) 
 
3 DISCUSSION 
 
This trial provides no evidence that early PC contact with a specialist PC nurse – who 
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outlined available palliative care services, and offered to arrange review by a palliative 
care physician ultimately improved patient symptoms or quality of life. If anything, there 
was a trend towards the opposite. There were non-significant trends for the place of 
death of early contact PC patients to be other than in an acute hospital, and for greater 
PC input during their final acute hospital admission.   
 
There was a trend for control patients’ scores for overall QoL, pain and appetite to be 
better than the early intervention group.  The trend might simply be due to chance 
imbalances between the treatment groups.  Early PC contact patients may have felt 
more comfortable reporting symptoms because of PC contact – less trying to “please 
the doctor”. These factors also may have contributed to the greater mean scores in the 
early PC contact group in the RSCL physical symptoms and psychological distress 
scales, and the pattern of scores in the MQOL.  Alternatively patients in the standard 
care group may have experienced a protective effect of denial.  Lung cancer patients 
who displayed a moderate or increasing level of denial over time reported better quality 
of life compared with those who displayed low levels of denial (p<0.0001) (20).  
 
There was a statistically significant difference in survival time favouring the control arm. 
The estimated effect was smaller and of marginal statistical significance when adjusted 
for gender, diagnosis, months since initial diagnosis and the oncologist’s baseline 
estimate of likely survival time. The observed survival differences are likely due to 
chance imbalances between the groups.  
 
Our results differ from those reported by others (10).   Differences in the eligibility of 
patients may have played a role in that our trial included patients with a range of cancer 
types, most of whom had recurrent cancer. The Boston trial recruited advanced lung 
cancer patients within 8 weeks of first cancer diagnosis.   The nature and ‘dose’ of the 
palliative care intervention also differed between our study and that reported from 
Boston.  In Boston, PC contact involved the patient meeting with a member of the PC 
team which consisted of 5 palliative care physicians and one advanced practice nurse, 
and 55% of the consultations were conducted by physicians, and 44% by the advanced 
practice nurse.  The median time for the first palliative care outpatient visit was 55 
minutes (21).  Subsequent contact in Boston was at least monthly in the outpatient 
setting.   
 
Our results also differ from those obtained in Project Enable (Educate, Nurture, Advise, 
Before Life Ends) (22), where the intervention involved not only specialist palliative care 
nurse educators, but also nurse practitioners, and palliative care physicians.  It used a 
case management, educational approach with monthly shared medical appointments to 
encourage patient activation, empowerment, and self-management. There was higher 
quality of life (P < 0.02), lower symptom intensity (P < 0.06), and lower depressed mood 
(P < 0.02) in Project Enable patients.  
 
Several strengths and limitations of our study deserve mention. In spite of 
randomization, there were differences between the groups in the numbers of patients 
with breast cancer, the time since initial cancer diagnosis, and the treating oncologist’s 
prediction of expected survival. Findings from a single institution and palliative care 
nurse consultant may not be generalizable. A larger, stratified multicentre trial is needed 
to reduce the likelihood of important imbalances, and to improve the generalisability of 
the results.   
 
A strong case can be made for further, rigorously-designed, large randomized trials in 
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differing health care settings of better-defined ‘early’ PC intervention in cancer patients 
with limited survival expectations, to determine effects on quality of life, quality of death, 
and survival.  Future studies should specify the issues that were addressed during the 
PC “consultation” such as pain management, symptom control, psychosocial and 
spiritual issues, prognosis, burdens and benefits of different treatment options, 
advanced care planning, and   preferences for place of care.  Similarly the endpoints of 
new trials should include repeated measures of quality of life, and measures of hope 
and denial.  Studies also need to distinguish between patients whose palliative care 
needs are straightforward and manageable by the oncologist versus more complex 
presentations (23). 
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Figure 1:    
Trial profile:  Qs = number of patients who undertook the assigned questionnaire 
battery. Following baseline, the MQOL and RSC were to be completed monthly whilst 
the SCNS was to be completed every 4 months. Completion rates at months 1, 3, 6, 9 
and 12 are shown. All patients with a baseline and at least one post-baseline 
assessment were included in the repeated measures analyses.  
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Figure 2 
 
(a) 
(b) 
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Figure 3 
  
(a) 
(b) 
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Legend for Figures 2 and 3:  Estimates are presented with 95% confidence intervals. 
An asterisk indicates a statistically significant difference at p<0.05. A larger score on the 
MQOL reflects a more favorable outcome, whilst a larger score on the SCNS and the 
RSC scales reflects a less favorable outcome. The baseline (i.e. month 0) estimate is 
the (unadjusted) mean score. The estimates for the mean post-baseline score to 12 
months, and the worst post-baseline score to 12 months, are from the ANCOVA 
models. The estimates at months 1 through 12 are from the MMRM analysis fitted to all 
available data from patients with a baseline and a least one post-baseline assessment 
(i.e. 86 patients for MQOL total score, 64 patients for SCNS total score, 86 patients for 
RSC Psychological Distress score, and 86 patients for RSC Physical Symptoms score).  
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Figure 4 
 
 
Log-rank test p-value = 0.014 
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Table 1.  Baseline Demographics and Clinical Characteristics of Study Patients 
 
 Early Palliative Care 
Contact group 
N=60 
Standard care 
group 
N=60 
Age in years: Mean (SD) 63 (11.2) 64 (11.1) 
Female sex: N (%) 28 (47%) 34 (57%) 
Partner: N (%)  40 (67%) 41 (68%) 
Education Year 10 or less: N (%) 23 (38%) 32 (53%) 
Australian born: N (%) 29 (48%) 36 (60%) 
Months since initial  
cancer diagnosis Mean (SD)  
(5 missing values) 
29 (40.0) 34 (53.0) 
Cancer diagnosis: N (%)    
 Gastrointestinal 20 (33%) 24 (40%) 
 Lung 12 (20%) 11 (18%) 
 Prostate 0 (0%) 2 (3%) 
 Breast 5 (8%) 12 (20%) 
 Gynaecologic 11 (18%) 8 (13%) 
 Other/Unknown primary 12 (20%) 3 (5%) 
Oncologist estimate of patient’s  
likely survival time: N (%) 
  
 4-12 weeks 1 (2%) 0 (0%) 
 3-6 months 9 (15%) 6 (10%) 
 6-12 months 33 (55%) 30 (50%) 
 >12 months 11 (18%) 20 (33%) 
 Not stated 6 (10%) 4 (7%) 
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Table 2: Severe symptoms (i.e. ever assigned a score > 5) reported on the MQoL 
within the three months prior to death 
 
Troublesome Symptom* 
 
Randomisation Group  
Total Intervention 
N=24 
Control 
N=23 
p-value** 
Pain 12 (50%) 8 (35%) 0.38 20 (43%) 
Tired 8 (33%) 7 (30%) 1.00 15 (32%) 
Appetite 9 (38%) 2 (9%) 0.04 11 (23%) 
Other 8 (33%) 3 (13%) 0.17 11 (23%) 
Weakness 8 (33%) 3 (13%) 0.17 11 (23%) 
Breathing 5 (21%) 3 (13%) 0.70 8 (17%) 
Sleep 3 (13%) 4 (17%) 0.70 7 (15%) 
Constipation 4 (17%) 2 (9%) 0.67 6 (13%) 
Nausea 2 (8%) 2 (9%) 1.00 4 (9%) 
Diarrhoea 1 (4%) 1 (4%) 1.00 2 (4%) 
        
*  Symptoms reported by subjects on multiple occasions appear only once in this 
table. Infrequently reported symptoms have been coded to other category 
** Fisher’s Exact Test 
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Table 3 Place of death, and palliative care contact during last admission 
 
 Early Palliative Care 
Contact group 
 
Standard care 
group 
 
P-value  
Place of death   0.46 
 Home 13 (22%) 8 (15%)  
  Hospice/Nursing Home 11 (19%) 8 (15%)  
 Acute Hospital 34 (59%) 37(70%)  
 Total 58 53  
    
Palliative care contact at 
last admission   
0.37 
 Yes 42 (86%) 29 (78%)  
 No 7 (14%) 8 (22%)  
 Total 49 37  
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